The Medical Research Council (MRC) has announced a £50 million investment in the new MRC Centre of Research Excellence in Mitochondrial Genome Therapeutics, which aims to enable new treatments into potentially fatal mitochondrial DNA diseases. It brings together leading experts from across disciplines to define how mutations in mitochondrial DNA (mtDNA) cause disease and translate that knowledge into therapies. The new Centre builds on the University's existing expertise in mitochondrial research at the MRC Mitochondrial Biology Unit. Each mitochondrion has its own DNA, distinct from the rest of the human genome, which is comprised of nuclear DNA. The MRC CoRE will harness emerging technologies to engineer the mitochondrial genome, delivering advanced models for study common disease-causing mtDNA mutations.